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Abstract
Background: Memory services often see people with early stage dementia who are largely independent and able
to participate in community activities but who run the risk of reducing activities and social networks. PRIDE is a self-
management intervention designed to promote living well and enhance independence for people with mild
dementia.
This study aims to examine the feasibility of conducting a definitive randomised trial comparing the clinical and
cost-effectiveness of the PRIDE intervention offered in addition to usual care or with usual care alone.
Methods/design: PRIDE is a parallel, two-arm, multicentre, feasibility, randomised controlled trial (RCT). Eligible
participants aged 18 or over who have mild dementia (defined as a score of 0.5 or 1 on the Clinical Dementia
Rating Scale) who can participate in the intervention and provide informed consent will be randomised (1:1) to
treatment with the PRIDE intervention delivered in addition to usual care, or usual care only. Participants will be
followed-up at 3 and 6 month’s post-randomisation. There will be an option for a supporter to join each
participant. Each supporter will be provided with questionnaires at baseline and follow-ups at 3 to 6 months.
Embedded qualitative research with both participants and supporters will explore their perspectives on the
intervention investigating a range of themes including acceptability and barriers and facilitators to delivery and
participation. The feasibility of conducting a full RCT associated with participant recruitment and follow-up of both
conditions, intervention delivery including the recruitment, training, retention of PRIDE trained facilitators, clinical
outcomes, intervention and resource use costs and the acceptability of the intervention and study related
procedures will be examined.
Discussion: This study will assess whether a definitive randomised trial comparing the clinical and cost-
effectiveness of whether the PRIDE intervention offered in addition to usual care is feasible in comparison to usual
care alone, and if so, will provide data to inform the design and conduct of a future trial.
Trial registration: ISRCTN, ISRCTN11288961, registered on 23 October 2019, http://www.isrctn.com/ISRCTN123456
78 Protocol V2.1 dated 19 June 2019.
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Background
Dementia challenges society, individuals and can have
profound effects on family carers. People with cognitive
impairment and dementia can experience ‘excess disabil-
ity’ due to stigmatisation, loss of independence and a
sense that relatives seek to take over their tasks and run
their lives [1, 2]. Low expectations mean that staff and
carers often don’t encourage people with dementia to
use their skills or learn new things, further contributing
to decline. Hobbies and interests are often lost early in
the disease process [3]. A review indicated that provision
of information and advice can improve quality of life in
dementia [4], but this needs to be delivered with ease as
alow-cost intervention to improve support and care.
Self-management interventions are a core part of
current UK health policy and provision for long-term
(chronic) conditions [5]. Such interventions can be deliv-
ered and received in a variety of ways (individually and
in a group) and may be computer-assisted, mail-
delivered, telephone-based or in a face-to-face format
[6]. The aim is to live well with chronic illness, man-
aging one’s condition and its emotional impact, and
maintain as active a life as possible [7]. The limited re-
search from self-management programmes for people
with dementia [6, 8, 9] suggests that self-management
programmes may address the current “care gap” in sup-
porting people living with early stage dementia [10].
The PRIDE study comprises five interrelated strands
investigating early/mild dementia. The first two strands
involved an epidemiological investigation into the risk
and protective factors associated with dementia in two
large longitudinal databases of older adults in England
and Brazil [11] and a qualitative exploration of social
discourses of dementia focusing on the themes of mem-
ory and independence, involving interviews and observa-
tions with adults ranging from those with no memory
problems to those 2 years post-diagnosis [12]. These two
studies contributed to the development of the PRIDE
intervention, along with existing literature, which was
then tested to inform present feasibility randomised con-
trolled trial. Findings from this feasibility RCT will be
used to inform on whether, a definitive randomised trial
comparing the clinical and cost-effectiveness of the self-
management PRIDE intervention is indicated.
Aims and objectives
The aim of the PRIDE feasibility randomised controlled
trial is to investigate the feasibility and acceptability of
conducting a future large-scale definitive randomised
controlled trial (RCT) to compare the clinical and cost
effectiveness of the PRIDE intervention delivered in
addition to usual care with usual care only for people
with mild dementia. The objectives of the study are to:
1. Determine the feasibility of recruitment and
acceptability of randomisation
2. Refine the eligibility criteria for a future definitive
RCT
3. Determine the relevance and acceptability to
patients / clinicians of the trial intervention
4. Determine the acceptability to patients / clinicians
of the trial procedures
5. Assess the ability of NHS sites to deliver the
intervention and assess training and support needs
6. Evaluate treatment fidelity when delivered through
NHS services
7. Determine the services and interventions provided
as usual care and evaluate methods for measuring
this
8. Assess outcome completion rates and determine
the relevance and acceptability of a range of clinical
outcome measures and obtain data to inform
selection of the primary outcome for a future RCT
9. Evaluate the utility and acceptability of resource use
questionnaires for use in an economic evaluation
alongside a future RCT
10. Conduct a comparative micro-costing of the PRIDE
intervention and usual care
11. Estimate the sample size required for a definitive
study
Methods/Design
The PRIDE study is a prospective, parallel, two-arm,
multicentre randomised feasibility trial with participants
individually allocated on a 1:1 ratio to treatment with
either usual care plus the PRIDE intervention, or usual
care alone. Participants will be followed up for up to 6
month’s post-randomisation. Embedded qualitative re-
search will be used to explore the experiences of study
participants, their supporters, and of facilitators deliver-
ing the interventions Fig 1.
Participants
Recruitment is taking place in six secondary care sites in
England: Humber Teaching NHS Foundation Trust, Derby
Teaching Hospitals NHS Foundation Trust, North West
Boroughs Healthcare NHS Foundation Trust, Oxford
Health NHS Foundation Trust, Central and North West
London NHS Foundation Trust and Leicestershire Partner-
ship NHS Trust.
Participants are identified for recruitment into the trial
in the following ways:
NHS recruitment pathway
Participants are being identified and recruited from NHS
services for people with dementia within participating
secondary care trusts. Potentially eligible participants are
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identified from patient lists of the participating services
and other clinical settings and records screened by a
member of the usual care team in order to ascertain ini-
tial suitability for the trial. The initial approach is being
made by a member of the patient’s usual care team and
is taking place either face-to-face or by invitation letter.
Join Dementia Research recruitment pathway
Through ‘Join Dementia Research’ (JDR), which is an
online self-registration service that enables volunteers
with memory problems or dementia, carers of those with
memory problems or dementia and healthy volunteers
to register their interest in taking part in research JDR is
funded by Department of Health working in partnership
with the charities Alzheimer Scotland, Alzheimer’s Re-
search UK and Alzheimer’s Society and is Health Research
Authority (HRA) endorsed.
There are two methods people with dementia can join
the trial through JDR. First, potential participants may
search the JDR database and can contact the coordinat-
ing centre directly once verbal consent is obtained to
pass on contact details to participating sites. Second,
sites are searching the JDR database and are contacting
registered potential participants. Initial screening is be-
ing undertaken against non-clinical eligibility criteria
and a patient information sheet about the study is being
Fig. 1 Participant pathway flowchart
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sent. Potential participants identified through JDR must
be resident in a catchment area of one of the participat-
ing sites. Those who are not are advised that they do not
meet the eligibility criteria for the study.
Self-referral recruitment pathway
Participants are also able to self-refer directly to the local
research teams or the coordinating centre. Potential par-
ticipants may become aware of the study through relevant
local and national charities and patient organisations and
through general promotion of the trial via posters.
Eligibility
Participants are eligible for the study if they:
 are a resident within the catchment area of one of
the participating NHS sites
 are aged over 18 years
 meet the Diagnostic and Statistical Manual of
Mental Disorders-Fourth Edition (DSM-IV) [13]
criteria for dementia of any type, including
Alzheimer’s, vascular, Lewy body type and mixed
 are able to engage with and participate in the
intervention in the judgement of the investigator or
designee,
 are able to provide informed consent in the
judgement of the investigator or designee
 are able to read and communicate in English
In addition, to be eligible for randomisation the par-
ticipant must be assessed as having mild dementia, de-
fined as a score of 0.5 or 1 on the Clinical Dementia
Rating Scale [14]. The exclusion criterion is living in in-
stitutional care.
 Participants may take part with or without a
supportive other. If taking part, the supporter will be
eligible for the study if they are:
 aged 18 or over
 able to engage with and participate in the
intervention
 able to provide informed consent and
 able to read and communicate verbally in English
Usual care
All participants will receive the services and interven-
tions usually available to people with dementia and their
family at the participating sites. This will naturally vary
between and within centres and may change over time.
Intervention
In addition to usual care, participants allocated to the inter-
vention will receive the PRIDE intervention, encompassing
manualised social, physical and cognitive domains for
people in the early stages of dementia. The manual is used
to guide participants during three facilitated sessions of
between 60 and 90min, held over 2 months. The trained
facilitator will ensure that the intervention is tailored to
meet the individual’s needs. The objectives of the PRIDE
intervention are:
1. To promote independence and facilitate living well
with dementia.
2. To enable the participant to maintain an active
lifestyle (e.g. exercise).
3. To aid the participant to have a healthy lifestyle
(e.g., smoking cessation).
4. To encourage the participant to maintain cognitive
activities.
5. To provide sign posting to local services and
resources about social, mental, and physical
activities and healthy lifestyle opportunities.
6. To help the person maintain their social roles.
The PRIDE manual is available to participants in a paper
or electronic (web-based) version. Participants may choose
either the paper or electronic version, or both. The man-
ual outlines chapters on communication, social connec-
tions, decision-making, keeping socially, mentally, and
physically active, finding a balance in activities, receiving a
diagnosis, and keeping healthy. Each participant is being
offered three sessions with a facilitator who will tailor the
intervention to their individual needs. Session 1 identifies
existing lifestyle choices, activities and routines valued by
the participant and identifies novel hobbies or everyday
tasks they might profit from and resources to support this.
The facilitator helps the participant identify social sup-
ports and explore whether the person feels they have
agency in everyday decision-making, and how to create
more opportunities for supported, but independent
decision-making. The facilitator will introduce the person
to the intervention manual and together plan a goal(s) to
work on over the next two months. Session 2 reviews pro-
gress from session 1. Goals may be refined according to
the participant and supporters’ experience of implementa-
tion and any needs which may have arisen in the first
month. New goals may also be set. Session 3 reviews pro-
gress again and final session focusses on developing plans
to maintain the changes placed during previous sessions.
Sessions 2 and 3 may also involve the facilitator participat-
ing in activities out in the community with the person or
participant and supporter based on their choices.
Adherence
Fidelity checks will take place to assess how well the
PRIDE intervention is being delivered according to the
intervention protocol, facilitator training and manual.
Checks will adhere to an intervention fidelity framework
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(Table 1 Change Consortium [15, 16] using the follow-
ing quality assurance parameters: using the following
quality assurance parameters:
Training
All facilitators delivering the PRIDE intervention attended
a 1-day standardised training session. Delivery and receipt
of training was observed and rated by two researchers (the
lead for fidelity and one other member of the research
team) using a bespoke training observation checklist. For
the purposes of comparison, trainees were asked to rate
the training according to the same criteria using a simpli-
fied checklist. The checklists listed core skills and key cri-
teria identified out of the content of the training and the
manualised intervention. Facilitator skills and understand-
ing of the intervention was measured through training
delivery techniques such as active participation as well as
observed behaviours such as skill acquisition and reflec-
tion via the checklist.
Analysis of resulting data will determine inter-rater re-
liability between coders to establish the extent to which
they attribute the same score to the same variable. Fre-
quencies will be used to determine the extent to which
the training maintained fidelity to what was intended.
Similar methods have been used in previous studies [17].
Delivery and receipt
To ensure comparable treatment between sites and
within dyads at sites, registers are being used to monitor
adherence to the intervention. Quality of facilitation is
managed using a generic job description.
To assess facilitator adherence to the manualised
intervention and participant receipt of the intervention,
focus groups will be held with a sample of facilitators
and with participants and supporters respectively. Facili-
tators are also completing a register of attendance for
each participant including number of sessions attended
and topic covered during each session. This will demon-
strate participant adherence to the intervention as well
as adherence to the manual.
Outcomes
Feasibility outcomes
The primary outcome of this study is the feasibility of con-
ducting a full RCT of the PRIDE intervention, determined
by a range of measures related to the study objectives. The
feasibility outcomes, which will be measured to meet the
objectives of this study, are shown in Table 2.
Clinical outcomes
Clinical outcomes will be measured to assess the rele-
vance and acceptability of these outcomes for use in a
future definitive RCT and to obtain information to in-
form selection of the primary outcome measure for a
future trial. The following clinical outcomes will be
assessed at baseline and at follow-up visits completed
at 3 and 6 months post-randomisation. Participants
randomised after 30 June 2019 will not have a 6-month
follow-up visit. For these participants, the follow-up
visit at 3 months will be their final visit:
Table 1 Fidelity assessment strategy
Goal Description Fidelity
Monitoring facilitator training
Standardised training All facilitators receive the same training programme • Training delivered by the same trainer(s)
• Attendance registers for training
• Training observation checklists
Facilitator skill acquisition All facilitators participate in the training in a similar way
Did training equip facilitators with required skills
• Completion of training exercises
• Training observation checklist
• Focus group
Monitoring intervention delivery
Comparable treatment All participants receive the same programme • Offer of 3 sessions
• Attendance register for 3 sessions
• All participants receive a manual
Risk to implementation Recruitment of suitable facilitators • Facilitator job description
Standardised delivery All facilitators using the same techniques and content from the
manual and training
• Intervention delivery checklist
• Focus group
Minimise drift in skills/delivery Adherence to training content and delivery across sites • Focus group
Monitoring receipt of intervention
Participant attendance and
engagement
Numbers of participants attending sessions
Participants identifying a goal(s)
• Attendance register for 3 sessions
• Register of topics/goals covered from
the manual
• Focus group
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Table 2 Feasibility objectives and outcomes
Feasibility objectives Feasibility outcomes
1. Determine the feasibility of recruitment
to a large-scale RCT
a. Aggregate data on potential participants within
NHS services
b. Number of patients assessed for eligibility /
consented / randomised
c. Number and proportion of potential participants
identified through NHS services, Join Dementia
Research and by self-referral who are eligible
d. Reasons for non-inclusion / non-eligibility
e. Monthly recruitment rate per site
f. Barriers and facilitators to recruitment
(focus groups)
2. Refine the eligibility criteria for a future
definitive RCT
a. Number of screening failures for eligibility,
post-consent
b. Participant and facilitator report (focus groups)
3. Determine the acceptability to patients /
clinicians of randomisation
a. Proportion of eligible patients that consent to
randomisation
b. Reasons for non-consent
c. Participant and facilitator report (focus groups)
4. Determine the relevance and acceptability
to patients / clinicians of the trial intervention
a. Premature discontinuation or non-attendance of
treatment and reasons
b. Feedback from participants and site staff delivering
the intervention
c. Participant and facilitator report (focus groups)
5. Determine the acceptability to patients /
clinicians of the trial procedures
a. Proportion of approached NHS sites that agree to
participate in the trial and reasons for non-participation
b. Proportion of eligible patients that consent to
randomisation
c. Reasons for non-consent
d. Withdrawals and losses to follow-up and reasons
e. Feedback from participants and staff (focus groups)
6. Assess the ability of NHS sites to deliver
the intervention
a. Measures of the feasibility of delivering the PRIDE
intervention within NHS settings:
i. Number / grade / experience of staff within
the service
ii. Staff turnover
iii. Time to treatment initiation
b. Measures of the recruitment and retention of PRIDE
facilitators during the study treatment period
c. Barriers to treatment delivery per protocol
(focus groups)
7. Assess training and support needs for NHS
staff delivering the intervention
a. Feedback on training delivered (focus groups)
b. Support offered / accepted (e.g. log of calls and
emails to central support lines)
8. Evaluate treatment fidelity when delivered
through NHS services
a. Measures of treatment fidelity including:
i. Adherence to intervention manual
ii. Uptake of activities
b. Feedback from participants and staff (focus groups)
9. Determine the services and interventions
provided as usual care and evaluate methods
for measuring this
a. Post-diagnostic care pathway
b. Services available
c. Uptake of services
10. Assess follow-up and outcome
completion rates
a. Response rate to follow-up assessment
b. Questionnaire completion rates
c. Amount of missing questionnaire data at item
and scale levels
11. Determine the relevance and acceptability
of a range of clinical outcome measures and
selection of the primary outcome for the main trial
a. Completion rates and reasons for non-completion
/ missing data
b. Estimates of clinically important differences,
variance and sensitivity to change for the clinical
outcome measures
c. Direct questions to participants regarding relevance
of measures
12. Evaluate the utility and acceptability of a. Completion rate and reasons for non-completion
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Outcomes for the person with dementia
 Activities of Daily Living measured using the
Lawton Instrumental Activities of Daily Living
(IADL) Scale [18].
 Health-related quality of life measured using the
EuroQoL Quality of Life Questionnaire (EQ-5D-5 L)
[19]
 Quality of life measured using the DEMQOL [20]
 Mood measured using the Geriatric Depression
Scale (GDS) – short form [21]
 Cognition measured using the Standardised Mini
Mental State Exam (S-MMSE) [22]
 Wellbeing measured using the Control, Autonomy,
Self-realisation and Pleasure (CASP) questionnaire
[23]
 Quality of relationships measured using the Impact
on Participation and Autonomy Questionnaire for
older people (IPAQ-O) [24]
 Positive emotions measured using the Positive
Psychology Outcome Measure (PPOM) [25]
 Social engagement measured using the number of
social contacts and leisure activities per week
 Global change (assessed by the person with
dementia and the supporter). At each follow-up time
point, participants will be asked to provide a rating
of their perceived change in relevant domains
(wellbeing and sense of independence) since
baseline, using a 5-point ordinal scale (much better,
a bit better, no change, a bit worse, much worse).
Outcomes for supporters (if participating)
 Health-related quality of life measured using the
EuroQoL Quality of Life Questionnaire (EQ-5D-5 L)
[19]
Health economic outcomes
 Resource use measured using a modified version of
the Client Service Receipt Inventory (CSRI) for
dementia [26]. Participants and supporters will be
asked to provide a retrospective report of resource
use in the preceding 3 months.
 Quality Adjusted Life Years (QALYs) calculated
using health related quality of life data collected
through the EQ-5D-5 L and DEMQOL.
Micro-costing of the PRIDE intervention determined
by collection of information from participating sites
regarding the staff time and resources for delivery of
the PRIDE intervention, including implementation,
training and delivery.
Sample size
As this is a feasibility study, a formal sample size calcula-
tion for between group comparisons of a primary outcome
is not appropriate. A sample size of 75 randomised partici-
pants will allow estimation of recruitment fraction with a
margin of error (half-width of 95% confidence interval) of
around 8 percentage points, and retention of 12 percent-
age points.
Recruitment
Recruitment started on 22 November 2018 and will end
on 30 June 2019. Participants randomised after 30 June
2019 will not have a 6-month follow-up visit. For these
participants the follow-up visit at 3 months will be their
final visit. Participants will be recruited from six second-
ary care sites in England. Whether identified in memory
clinics, via PICs, through JDR or by self-referral, the in-
vestigator or their nominee, e.g. from the research team
or a member of the participant’s usual care team, will in-
form the potential participant of all aspects pertaining to
participation in the study and a written Participant In-
formation Sheet will be provided.
Participants identified through JDR or by self-referral
will be registered as outpatients of the memory clinic of
the participating NHS trust at enrolment in the trial.
Participants will be advised that they can choose to
take part either with a supportive other or on their own.
If the participant chooses to take part with a supporter
they will be asked to nominate a person, who if eligible,
Table 2 Feasibility objectives and outcomes (Continued)
Feasibility objectives Feasibility outcomes
resource use questionnaires for use in an
economic evaluation alongside a future RCT
/ missing data
13. Comparative micro-costing of PRIDE
intervention
and usual care
a. Staff time and resources for delivery of
PRIDE intervention
b. Other service use
14. Estimate the sample size required for a
definitive study
a. Primary outcome selection
b. Variability in the outcome
c. Withdrawals and losses to follow-up
15. Determine the resources required
for a full trial
a. Sample size, recruitment rate (number of sites /
recruitment period), staffing and resources
(for recruitment, treatment and follow-up)
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will be invited to join the study (note that it will also be
possible for a supporter to assist the participant, without
participating in the study in their own right). The poten-
tial supporter will be provided with written information
about the study and be asked to attend the screening
and baseline visit with the participant, where informed
written consent will be obtained.
Consent
Trial participants have mild dementia, and therefore are
generally expected to be competent to give informed con-
sent for participation, provided that appropriate care is
taken in explaining the research and sufficient time is
allowed for them to reach a decision. If it is helpful for a
supporter to be involved, we would aim to ensure that this
is done wherever possible. In seeking consent, we will fol-
low current guidance from the British Psychological Society
on evaluation of capacity [27]. In this context, consent has
to be regarded as a continuing process and will be continu-
ally checked through discussion with participants during
the assessments. If the participant’s level of impairment in-
creases during the course of their involvement in the study
to the extent that, in the judgement of the investigator (or
designee), they do not have capacity to provide continued
informed consent for their ongoing participation in the trial
at that time, the research activity would be discontinued.
Where a supporter is also participating in the trial, the
supporter will be asked to provide written informed con-
sent for their own participation in the trial. The sup-
porter’s decision to participate or not will not affect
involvement of the participant. Supporters may decline
consent to participate in the trial on their own behalf
but be present during and intervention sessions and re-
searcher follow up appointments in order to support the
person with dementia, should they request this. In this
case, their involvement will be recorded but no further
details or data will be collected.
Follow-up
Each participant will be in the trial for a maximum of 6
months, from randomisation to final follow-up. Table 3
describes the study procedures and assessments at each
time point including screening and baseline. All baseline
and follow-up visits will be completed face-to-face with
a researcher.
The duration of the trial is expected to be up to 24months
from recruitment of the first participant to reporting.
Withdrawal
Participants can withdraw from the trial at any time
without affecting their current or future care. Reasons
for withdrawal will be sought and recorded.
Participants in the intervention group may discontinue the
PRIDE intervention at any time. Reasons for discontinuation
from the intervention will be recorded. Participants who pre-
maturely discontinue the trial intervention will be asked to
remain in the trial for follow-up. If participants who prema-
turely discontinue the trial intervention choose to also with-
draw from trial follow-up, the reason for withdrawal will be
requested, and documented where given.
Supporters may also withdraw from the trial as a whole
or choose to discontinue their involvement in the trial
intervention. Doing so will not affect the participants con-
tinuation in the trial. The withdrawal or discontinuation
of supporters will be recorded, with reasons for with-
drawal or discontinuation requested, and documented
where given. If the participant wishes to identify an alter-
native supporter to participate in the trial with them, they
will be able to do so. The alternative supporter will pro-
vide consent to participate and the change of supporter
will be documented.
Randomisation
Participants will be allocated at the individual level to
intervention or control on a 1:1 ratio using minimisation
with a probabilistic element. The minimisation variables
will be study site, sex, age (< 80 or ≥ 80) and medication
for dementia (any versus none). The allocation algorithm
will be created by the Nottingham Clinical Trials Unit
(NCTU) in accordance with their Standard Operating
Procedure (SOP) and held on a secure server. The inves-
tigator or authorised designee will use the remote,
internet-based randomisation system to obtain the treat-
ment allocation for each participant.
Following randomisation, participants will be notified
of their treatment allocation by an unblinded member of
the research team and their GP will be notified of their
involvement in the trial.
Blinding
Due to the nature of the intervention, blinding of treat-
ment allocation is impossible for participants and the staff
delivering it. The study outcome data at all the time points
will be collected by members of the local research team
who will be blind to group allocation. The researchers
conducting the outcome assessment visits will record in-
stances of unblinding. The trial statisticians will remain
blinded to treatment allocation until after database lock.
Adverse events
No adverse reactions have been identified in previous tri-
als of social and psychological interventions for people
with dementia [9, 28, 29]. The risks of the current trial
have therefore been assessed as low and there are unlikely
to be adverse events resulting from the trial. For this rea-
son, adverse events (AEs) and serious adverse events
(SAEs) will not be routinely collected for this trial.
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The assessments for participants will be limited in
duration and not unduly long or stressful. Researchers
and facilitators delivering the intervention will be trained
to identify and deal with any distress exhibited by trial
participants during trial activities and will make referrals
(e.g. to the participant’s GP) if needed.
Data collection, management and analysis
Data collection and clinical assessments will be in person
with the researcher and conducted in the participant’s
home (or other suitable community or NHS venue, as
appropriate, depending on participant preference). Partici-
pant questionnaires at baseline, follow-up at 3 and 6
months will be self-completed by participants during the
visits. If the participant chooses to take part with a sup-
porter, the designated supporter will be asked to complete
questionnaires also at baseline and follow-up at 3 and 6
months. If the supporter is not present during the follow-
up visit, the questionnaire may be posted to them.
Questionnaire data will be entered onto the trial database
which includes programmed validation checks. Checks will
include missing data (including missing forms), out of
Table 3 Study procedures and assessments
Months 0 0–2 3 6f
Study Procedures and Assessments: Participants Visit 1 RANDOMISATION Intervention period Visit
2
Visit
3
Baseline Follow-up
Initial eligibility screena X Intervention:
PRIDE intervention (3 sessions with a PRIDE
facilitator) in addition to usual care
Control:
Usual care only
Informed consentb X
Demographic information X
Post-consent eligibility screen: Clinical Dementia
Rating (CDR) Scalec
X
Lawton IADL Scale X X X
EuroQoL Quality of Life (EQ-5D-5 L) X X X
DEMQOL X X X
Geriatric Depression Scale (GDS) X X X
Standardised Mini Mental State Exam (SMMSE) X X X
Control, Autonomy, Self-realisation and Pleasure
(CASP-19)
X X X
Impact on Participation and Autonomy (IPAQ-O) –
Social Relations Sub-Scale
X X X
Positive Psychology Outcome Measure (PPOM) X X X
Social Engagement Checklist X X X
Global Change Measure X X
Client Service Receipt Inventory (CSRI) X X X
Focus groups with facilitators and participants /
supporters
Xd
Study Procedures and Assessments: Supporters Visit 1 Visit
2
Visit
3f
Baseline Follow-up
Informed consent X
Supporter questionnaire: EuroQoL Quality of Life
(EQ-5D-5 L)e
X X X
Global Change Measuree X X
Supporter questionnaire: Client Service Receipt
Inventory (CSRI)e
X X X
aParticipants not included in the trial will be recorded on the screening log, with reasons for non-inclusion documented
bAll participants providing consent will be enrolled on the trial database, with demographic details and screening assessments recorded
cParticipants who are identified as ineligible for randomisation during the post-consent eligibility screen will be defined as screen failures and will not proceed
to randomisation
dSeparate focus groups will be completed with a facilitator and a subset of participants and supporters
eSupporter questionnaires will be passed to supporters during participant visits (if present) for completion during the visit or will be posted with a prepaid
envelope for return to the Coordinating Centre
fParticipants randomised after 30th June 2019 will not have a 6-month follow-up visit, and their last visit will be at visit 2
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range values, illogical entries and invalid responses. Data
collection and retention rates will be monitored by the Trial
Management Group (TMG) throughout the trial.
Statistical analyses
Data analysis will primarily be descriptive to address the
feasibility aims of the study. All analyses will be docu-
mented in a Statistical Analysis Plan, which will be finalised
prior to database lock. Feasibility outcomes will be esti-
mated using descriptive statistics (with 95% confidence in-
tervals [CI] if relevant) and will include recruitment rates,
follow-up rates, amount of missing data, and intervention
adherence. The rate of protocol adherence will be reported
within the intervention group in terms of participants who
adhere to the intervention they were allocated to receive
and who comply with the scheduled treatment visits.
Key baseline characteristics (age, gender) will be com-
pared between trial participants and the ineligible and
non-consenting patients, to ascertain adequacy of inclu-
sion/exclusion criteria and likely generalisability of the
trial to the required targeted population.
Similarly, we will compare the key patient characteristics
between those followed-up and those lost to follow-up
and investigate how similar this is across the treatment
arms to assess possible attrition bias in data collection.
A baseline table will compare important demographic
and clinical characteristics between the two treatment
arms. It is not an objective of the feasibility study to obtain
estimates of intervention effect on clinical outcomes and
so the clinical outcomes will be presented descriptively.
Global change outcomes will be used to categorise im-
provers / non-improvers for anchor-based analysis of
minimum clinically important differences and responsive-
ness to change of relevant, related outcome measures.
Trial management and oversight
Nottingham Clinical Trials Unit (NCTU) is the coordinat-
ing centre and responsible for all trial management activ-
ities. Trial oversight will be provided by an independent
Trial Steering Committee (TSC) who will monitor trial pro-
gress and assess feasibility. As the trial interventions and
procedures have been assessed as low risk, safety oversight
will be performed by the TSC without the need for a separ-
ate independent Data Monitoring Committee.
The Trial Management Group (TMG) responsible for
the day-to-day delivery of the trial will also meet
monthly and report to the TSC on progress.
Qualitative sub-study
Facilitator and participant (supporters, where present)
focus groups will be arranged to explore perspectives
on the intervention and investigate a range of themes
including, but not limited to:
 Acceptability of the intervention (manual, sessions,
facilitation)
 Barriers and facilitators to delivery of the
intervention
 Experience of the intervention
 Factors that may mediate or moderate the
effectiveness of the intervention
 Skills and competencies required to deliver the
intervention
 Barriers and facilitators to continued use of the
intervention
 Acceptability of the outcome measures (quantity,
content, ability to complete)
 Acceptability of the trial procedures (recruitment,
consent, randomisation and activities throughout
the follow-up period)
Utilising a focus group approach will help people to
identify and clarify their views in relation to others who
have experienced the same intervention [30] and support
sharing of their ideas and similar or different opinions.
A schedule of topics and questions will help guide dis-
cussion to produce final themes [31]. Field notes will be
used to record discussions and agreement. Results will
be used to explore potential explanations for the quanti-
tative findings and identify emergent factors that influ-
ence the uptake and impact of the intervention and
other trial procedures for a future large trial.
Protocol amendments
All methods described here reflect the current study
protocol (V2.1 dated 19June2019). This protocol
Additional file 1 conforms to the SPIRIT recommenda-
tions [32]. See Table 4 for a summary of protocol
amendments. All amendments to the protocol have been
approved by the trial sponsor, Research Ethics Commit-
tee and local R&D departments prior to implementation.
Confidentiality
Participant confidentiality will be ensured by allocating
participants a unique identification number to corres-
pond to treatment data in the computer files.
If information is disclosed during the study that could
pose a risk of harm to the participant or others, the re-
searcher will discuss this with the CI and where appro-
priate report accordingly.
Data generated as a result of this trial will be available
for inspection on request by appropriate organisations
and bodies such as the REC and the regulatory authorities.
Discussion
With the prevalence of dementia growing as the popula-
tion ages, the imperative to develop novel interventions
which are acceptable and effective is globally recognised
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by the governments and health departments of nations
worldwide (e.g. UK Department of Health, 2016; US
Department of Health and Human Services, 2012). In-
creased public awareness and a drive toward early diag-
nosis can lead to dementia being identified while still
mild, which presents the opportunity to offer interven-
tions the person with dementia (and their family) can ac-
tively play a part in. The development of psychological
interventions promoting social inclusion, dignity and the
positive contributions to society will reduce the current
challenges that are faced by people with mild dementia.
Many people with dementia remain undiagnosed and
memory services see many people in the early stages of
dementia who are independent and are able to partici-
pate in community activities. Therefore, there is a need
to improve early diagnosis, reduce discrimination and
develop an intervention with improved access to infor-
mation and advice.
The provision of psychosocial interventions built on
self-management in this early stage may lead to individ-
uals being able to maintain some independence and re-
main a part of their community [33]. Indeed, people
with dementia have the agency and desire to shape their
lives [34] and this can be capitalised on. This study may
also give a potential solution and share post-diagnostic
experiences of many people with dementia and carers
[35]. As part of the research programme social and life-
style changes were investigated to reduce risk and by
understanding the social impact of dementia and an ef-
fective PRIDE intervention was developed. The interven-
tion manual focuses on promoting independence and
quality of life for people with mild dementia family and
friends that support them.
Through the PRIDE programme we have created an
intervention we hope will be an effective tool to help
support independence for longer to reduce stigma and
social exclusion, and to improve communication and
wellbeing. The robust development and evaluation of
such an intervention is necessary [36].
A comparison of the PRIDE social intervention plus
usual care with usual care alone has been identified as
an important research question. However, there is un-
certainty if the NHS services are able to deliver the
intervention and are willing to recruit, and whether
patients will be willing to be randomised to a study with
several intervention sessions. The cost implications will
be another uncertainty alongside any social circum-
stances of the patient and carers.
The PRIDE feasibility study will provide data essential
to design and conduct a larger trial comparing the out-
comes and costs of the PRIDE intervention with usual
care to promote and enhance independence and quality
of life for people with mild dementia and carers that
support them.
Trial status
Protocol version 2.1 22 May 2019. Recruitment com-
menced in November 2018 and is expected to continue
until the end of June 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3838-x.
Additional file 1. VITA SPIRIT 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents.
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